Profile Previews

Get a glimpse into our company and investor data—powered by the PitchBook Platform

Cirius Therapeutics

Cirius Therapeutics
2015 FOUNDED
PRIVATE STATUS
11-20 EMPLOYEES
IPO LATEST DEAL TYPE (Cancelled)
$86.2M LATEST DEAL AMOUNT
5 INVESTORS
Description

Developer of an insulin sensitizer drug designed for the treatment of nonalcoholic liver disease. The company's insulin sensitizer is used to treat nonalcoholic steatohepatitis which is characterized by buildup of fat and inflammation in the liver, may be accompanied by fibrosis and can progress to life-threatening cirrhosis or liver cancer, enabling healthcare providers to treat patients of liver and metabolic diseases and avoid recurrence of nonalcoholic steatohepatitis.

Formerly Known As
Octeta Therapeutics
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Drug Discovery
Primary Office
  • 12651 High Bluff Drive
  • Suite 150
  • San Diego, CA 92130
  • United States
Request full access to PitchBook

You’re viewing a free company profile from the PitchBook Platform. To explore Cirius Therapeutics’s full profile, request a free trial.

Cirius Therapeutics Valuation and Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. IPO 20-Dec-2019 $86.2M Cancelled Clinical Trials - Phase 3
4. Early Stage VC (Series A3) 10-May-2019 00.00 000.00 00000 Completed Clinical Trials - General
3. Early Stage VC (Series A3) 23-Aug-2018 000 000.00 00000 Completed Startup
2. Early Stage VC (Series A2) 10-Apr-2017 $40M $56.4M 0000 Completed Startup
1. Early Stage VC (Series A1) 19-May-2016 $16.4M $16.4M 000.00 Completed Startup
To view this company’s complete deal history including valuation and funding, request access »

Cirius Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned
Series A3 0,000,000 00.000000 00 00.00 00.00 00 00.00 0.000
Series A2 00,000,000 00.000000 00 00.00 00.00 00 00.00 00.000
Series A1 17,069,451 $0.001000 8% $1 $1 1x $1 17.25%
To view this company’s complete Cap Table, request access »

Cirius Therapeutics Competitors (47)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Tioga Pharmaceuticals Venture Capital-Backed San Diego, CA 00 0000 000000 - 000 0000
000000000 Venture Capital-Backed San Diego, CA 00 00000 000000000 00000
0000000000 0000000 Venture Capital-Backed Mont-Saint-Guibert, Belgium 00 00000 00000000000 00000
00000 000000 Venture Capital-Backed New York, NY 0000 0000000000 0 0000
000000000(00000000 Formerly VC-backed New York, NY 000 00000 000000 - 000 00000
To view this company’s complete list of competitors, request access »

Cirius Therapeutics Investors (5)

Investor Name Investor Type Holding Investor Since Participating Rounds Board
Seat
Contact
Info
Adams Street Partners Fund of Funds Minority 000 0000 000000 0
Frazier Healthcare Partners Venture Capital Minority 000 0000 000000 0
Hopen Life Science Ventures Venture Capital Minority 000 0000 000000 0
Novo Holdings Corporate Venture Capital Minority 000 0000 000000 0
Renaissance Venture Capital Fund Fund of Funds Minority 000 0000 000000 0

Cirius Therapeutics Executive Team (5)

Name Title Board
Seat
Contact
Info
Robert Baltera Jr. Chief Executive Officer, President and Board Member
Brian Farmer Chief Financial Officer and Chief Business Officer
Jerry Colca Ph.D Chief Scientific Officer
Howard Dittrich MD Chief Medical Officer

1 Former Executive

You’re viewing 4 of 5 executives. Get the full list »

Cirius Therapeutics Board Members (9)

Name Representing Role Since Contact
Info
Daniel Estes Ph.D Frazier Healthcare Partners Board Member 000 0000
David Van Andel Cirius Therapeutics Board Member 000 0000
Dennis Fenton Ph.D Self Board Member 000 0000
Elaine Sun Self Board Member 000 0000
Michael Jandernoa Cirius Therapeutics Board Member 000 0000

1 Former Board Member

You’re viewing 5 of 9 board members. Get the full list »